公开(公告)号：US12031137B2

公开(公告)日：2024-07-09

申请号：US17302113

申请日：2021-04-23

Applicant: RSEM, LIMITED PARTNERSHIP

Inventor： Przemyslaw Sapieha ,  Frédérick Antoine Mallette ,  Malika Oubaha ,  Normand Beaulieu ,  Ariel Wilson

IPC: A61K47/68 ,  A61K31/155 ,  A61K31/7088 ,  A61K38/17 ,  A61P3/04 ,  C07K16/28 ,  C12N15/113 ,  C12N15/62

CPC classification number: C12N15/1138 ,  A61K31/155 ,  A61K31/7088 ,  A61K38/179 ,  A61P3/04 ,  C07K16/2863 ,  C07K2319/30 ,  C12N2310/111 ,  C12N2310/122 ,  C12N2310/531

Abstract: Described herein are compositions and methods for modulating cellular senescence of a cell or induction of the senescence-associated secretory phenotype (SASP) in a cell. The methods generally comprise modulating the level or activity of IRE1a as a mean to control cellular senescence and induction of the SASP. Also described are methods for treating and preventing ocular vascular diseases comprising contacting cells in an eye of a subject with a biguanide compound and ophthalmic compositions comprising a biguanide compound.

公开(公告)号：US10738122B2

公开(公告)日：2020-08-11

申请号：US15507407

申请日：2015-09-08

Applicant: RSEM, LIMITED PARTNERSHIP

Inventor： Przemyslaw Sapieha ,  Normand Beaulieu

IPC: A61K47/68 ,  C12N15/62 ,  C07K16/28 ,  A61K31/713 ,  A61K31/7105 ,  C07K14/71 ,  C07K16/22 ,  A61K39/395 ,  C12N15/113 ,  A61K39/00 ,  A61K38/00

Abstract: The present invention provides novel compounds compositions and methods for (i) treating or preventing inflammation; and (ii) preventing or reducing hyperactivation of innate immune response, by inhibiting NRP1-dependent cell-signaling. Also provided are compounds, composition, and methods of specifically inhibiting SEMA3A-mediated cell signaling.

公开(公告)号：US20140343051A1

公开(公告)日：2014-11-20

申请号：US14245062

申请日：2014-04-04

Applicant: RSEM Limited Partnership ,  Universite de Montreal

Inventor： GUY SAUVAGEAU ,  JOSEE HEBERT ,  CAROLINE PABST

IPC: A61K31/519 ,  A61K31/5377 ,  G01N33/50 ,  A61K45/06

CPC classification number: A61K31/519 ,  A61K31/522 ,  A61K31/5377 ,  A61K45/06 ,  G01N33/5073

Abstract: Novel methods for modulating acute myeloid leukemia stem/progenitor cell expansion and/or differentiation are disclosed. These methods are based on the use of aryl hydrocarbon receptor (AhR) modulators and/or compounds of formula I or II Screening assays to identify compounds that may be useful for inhibiting and/or eliminating AML initiating cells using AhR modulators and/or the compounds of formula I or II are also disclosed. The use of pharmaceutically acceptable agonists of the AhR for preventing or inhibiting minimal residual disease (MRD) in an AML patient is also disclosed.

Abstract translation: 公开了用于调节急性骨髓性白血病干/祖细胞扩增和/或分化的新方法。 这些方法基于芳基烃受体（AhR）调节剂和/或式I或II化合物的使用筛选测定来鉴定可用于使用AhR调节剂和/或化合物抑制和/或消除AML起始细胞的化合物 还公开了式I或II的化合物。 还公开了使用药物可接受的AhR激动剂来预防或抑制AML患者中的最小残留病（MRD）。

公开(公告)号：US20190359718A1

公开(公告)日：2019-11-28

申请号：US16422273

申请日：2019-05-24

Applicant: RSEM, LIMITED PARTNERSHIP

Inventor： Przemyslaw Sapieha ,  Normand Beaulieu

IPC: C07K16/28 ,  A61K31/713 ,  C07K14/71 ,  A61K31/7105 ,  C07K16/22 ,  A61K39/395 ,  C12N15/113

Abstract: The present invention provides novel compounds compositions and methods for (i) treating or preventing inflammation; and (ii) preventing or reducing hyperactivation of innate immune response, by inhibiting NRP1-dependent cell-signaling. Also provided are compounds, composition, and methods of specifically inhibiting SEMA3A-mediated cell signaling.

公开(公告)号：US20180030455A1

公开(公告)日：2018-02-01

申请号：US15784499

申请日：2017-10-16

Applicant: RSEM, LIMITED PARTNERSHIP

Inventor： PRZEMYSLAW SAPIEHA

IPC: C12N15/113 ,  A61K31/713 ,  G01N33/68 ,  A61K38/17 ,  A61K9/00 ,  C07K16/18 ,  C12Q1/68 ,  A61K31/7088 ,  G01N33/50 ,  A61K39/00 ,  A61K35/30

CPC classification number: C12N15/1138 ,  A61K9/0048 ,  A61K31/7088 ,  A61K31/713 ,  A61K35/30 ,  A61K38/17 ,  A61K38/179 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/76 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/30 ,  C12Q1/6897 ,  G01N33/5023 ,  G01N33/6893 ,  G01N2333/705 ,  G01N2500/10 ,  G01N2800/164

Abstract: Described herein is a method of preventing or treating ocular vascular hyperpermeability including macular edema, in a subject comprising inhibiting Sema3A activity. Also disclosed are compositions and their use for preventing or treating Sema3A-dependent ocular vascular hyperpermeability.

公开(公告)号：US20180030112A1

公开(公告)日：2018-02-01

申请号：US15548749

申请日：2016-02-09

Applicant: UNIVERSITÉ DE MONTRÉAL ,  RSEM, LIMITED PARTNERSHIP

Inventor： Claude Perreault ,  Diana Paola Granados ,  Jean-Sébastien Delisle ,  Pierre Thibault ,  Sébastien Lemieux

IPC: C07K14/74 ,  C07K7/08 ,  A61K35/17 ,  C07K1/04 ,  A61K35/13 ,  A61K39/00 ,  C07K7/06

Abstract: Novel minor histocompatibility antigens (MiHAs) are described. These novel MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these novel MiHAs are also described. The present application also discloses the use of these novel MiHAs, and related compositions, nucleic acids and cells, in applications related to cancer immunotherapy, for example for the treatment of hematologic cancers such as leukemia.

公开(公告)号：US20240301429A1

公开(公告)日：2024-09-12

申请号：US18675928

申请日：2024-05-28

Applicant: RSEM, LIMITED PARTNERSHIP

Inventor： PRZEMYSLAW SAPIEHA ,  FRÉDÉRICK ANTOINE MALLETTE ,  MALIKA OUBAHA ,  NORMAND BEAULIEU ,  ARIEL WILSON

IPC: C12N15/113 ,  A61K31/155 ,  A61K31/7088 ,  A61K38/17 ,  A61P3/04 ,  C07K16/28

CPC classification number: C12N15/1138 ,  A61K31/155 ,  A61K31/7088 ,  A61K38/179 ,  A61P3/04 ,  C07K16/2863 ,  C07K2319/30 ,  C12N2310/111 ,  C12N2310/122 ,  C12N2310/531

Abstract: Described herein are compositions and methods for modulating cellular senescence of a cell or induction of the senescence-associated secretory phenotype (SASP) in a cell. The methods generally comprise modulating the level or activity of IRE1a as a mean to control cellular senescence and induction of the SASP. Also described are methods for treating and preventing ocular vascular diseases comprising contacting cells in an eye of a subject with a biguanide compound and ophthalmic compositions comprising a biguanide compound.

公开(公告)号：US20230265199A1

公开(公告)日：2023-08-24

申请号：US18188707

申请日：2023-03-23

Applicant: RSEM, LIMITED PARTNERSHIP

Inventor： Przemyslaw Sapieha ,  Normand Beaulieu

IPC: C07K16/28 ,  A61K31/713 ,  A61K31/7105 ,  C07K14/71 ,  C07K16/22 ,  A61K39/395 ,  C12N15/113

CPC classification number: C07K16/2863 ,  A61K31/713 ,  A61K31/7105 ,  C07K14/71 ,  C07K16/22 ,  A61K39/395 ,  C12N15/113 ,  A61K2039/505

Abstract: The present invention provides novel compounds compositions and methods for (i) treating or preventing inflammation; and (ii) preventing or reducing hyperactivation of innate immune response, by inhibiting NRP1-dependent cell-signaling. Also provided are compounds, composition, and methods of specifically inhibiting SEMA3A-mediated cell signaling.

公开(公告)号：US20200208159A1

公开(公告)日：2020-07-02

申请号：US16808611

申请日：2020-03-04

Applicant: RSEM, LIMITED PARTNERSHIP

Inventor： PRZEMYSLAW SAPIEHA

IPC: C12N15/113 ,  A61K38/17 ,  G01N33/50 ,  A61K31/7088 ,  A61K31/713 ,  C07K16/18 ,  A61K9/00 ,  C12Q1/6897 ,  G01N33/68

Abstract: Described herein is a method of preventing or treating ocular vascular hyperpermeability including macular edema, in a subject comprising inhibiting Sema3A activity. Also disclosed are compositions and their use for preventing or treating Sema3A-dependent ocular vascular hyperpermeability.

公开(公告)号：US20200056186A1

公开(公告)日：2020-02-20

申请号：US16335896

申请日：2017-09-09

Applicant: RSEM, LIMITED PARTNERSHIP

Inventor： PRZEMYSLAW SAPIEHA ,  FRÉDÉRICK ANTOINE MALLETTE ,  MALIKA OUBAHA ,  NORMAND BEAULIEU ,  ARIEL WILSON

IPC: C12N15/113 ,  A61K38/17 ,  A61K31/155 ,  A61K31/7088 ,  A61P3/04 ,  C07K16/28

Abstract: Described herein are compositions and methods for modulating cellular senescence of a cell or induction of the senescence-associated secretory phenotype (SASP) in a cell. The methods generally comprise modulating the level or activity of IRE1a as a mean to control cellular senescence and induction of the SASP. Also described are methods for treating and preventing ocular vascular diseases comprising contacting cells in an eye of a subject with a biguanide compound and ophthalmic compositions comprising a biguanide compound.